Amide proton transfer-weighted (APTw) CEST MRI in clinical routine for single time point diagnosis of pseudoprogression in IDH-wildtype glioblastoma
Neuro-Oncology · 01.03.2026 · 28 (3) · 790-801
DOI: 10.1093/neuonc/noaf261 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 13.11.2025. Verfasst von Thomas Zeyen und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurooncology, Centers for Neurology and Integrated Oncology (CIO), University Hospital Bonn, Bonn, Germany (T.Z., J.W., N.S., C.S., U.…. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Magnetic Resonance Imaging, Isocitrate Dehydrogenase. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical -Faculty, University of Bonn, Else Kroener Fresenius Stiftung.
Abstract (Originalsprache)
Background
Differentiating progressive disease (PD) from treatment-related effects (TRE) in glioblastoma remains challenging, particularly at single time point evaluations. TRE can occur at any disease stage, and its underlying biology is poorly understood. This study evaluates the clinical feasibility and diagnostic performance of amide proton transfer-weighted (APTw) MRI in this challenge.
Methods
Following the integration of APTw MRI into the routine clinical workflow for brain tumor imaging, we screened a total of 870 scans from 626 patients. APTw signal (voxel-based measurement) was automatically quantified in gadolinium-enhanced T1w and FLAIR regions of interest using a deep learning-based approach for 3D tumor segmentations. PD and TRE were compared using unpaired t-tests, and diagnostic accuracy was assessed via ROC- and logistic regression analysis.
Results
Among 256 MRI scans of 143 patients with glioblastoma, 65 scans showed PD (n = 42) or TRE (n = 23). The median APTw signal was higher in PD (2.23%) vs TRE (1.67%; P = .0001). ROC analysis showed an area under the curve (AUC) of 0.82. In patients with early PD or TRE (<6 months post-radiotherapy), the AUC increased to 0.93. Anti-angiogenic therapy decreased APTw signal (P < .01). Combining APTw MRI with DWI and PWI improved diagnostic accuracy (AUC = 0.90).
Conclusions
APTw MRI is a non-invasive imaging tool that is feasible for clinical routine and aids in differentiation of early progression from pseudoprogression in glioblastoma. Its diagnostic accuracy decreases with application of anti-angiogenic treatment and at later follow-up time points. Highest diagnostic accuracy was found in a multimodal approach combining APTw MRI, PWI and DWI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurooncology, Centers for Neurology and Integrated Oncology (CIO), University Hospital Bonn, Bonn, Germany (T.Z., J.W., N.S., C.S., U.H.).
- Department of Radiology, Brigham and Womeńs Hospital, Harvard Medical School, Boston, Massachusetts (T.Z., I.K., F.K., D.P.).
- Department of Neuroradiology, University Hospital Bonn, Bonn, Germany (I.K., M.Z., A.R., D.P.).
- German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany (A.D.).
- Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany (S.R.).
- Department of Vascular Neurology, Center for Neurology, University Hospital Bonn, Bonn, Germany (J.W.).
ORCID-Profile: Thomas Zeyen, Johannes Weller, Anna-Laura Potthoff, Matthias Schneider, Daniel Paech
Förderung
- Medical -Faculty
- University of Bonn
- Else Kroener Fresenius Stiftung
- Medical Faculty of the University of Bonn
- German Research Foundation
- Medical Faculty
Zitieren
APA
Zeyen, T., Krause, I., Decker, A., Kroh, F., Regnery, S., Weller, J., Schaefer, N., Zidan, M., Potthoff, A. L., Schneider, M., Friker, L. L., Keupp, J., Katemann, C., Layer, J. P., Schaub, C., Gkika, E., Vatter, H., Pietsch, T., Radbruch, A., …, & Paech, D. (2026). Amide proton transfer-weighted (APTw) CEST MRI in clinical routine for single time point diagnosis of pseudoprogression in IDH-wildtype glioblastoma. Neuro-Oncology, 28(3), 790-801. https://doi.org/10.1093/neuonc/noaf261
Vancouver
Zeyen T, Krause I, Decker A, Kroh F, Regnery S, Weller J, et al. Amide proton transfer-weighted (APTw) CEST MRI in clinical routine for single time point diagnosis of pseudoprogression in IDH-wildtype glioblastoma. Neuro-Oncology. 2026;28(3):790-801. doi:10.1093/neuonc/noaf261
BibTeX
@article{Zeyen2026,
author = {Zeyen, Thomas and Krause, Inga and Decker, Andreas and Kroh, Florian and Regnery, Sebastian and Weller, Johannes and Schaefer, Niklas and Zidan, Mousa and Potthoff, Anna-Laura and Schneider, Matthias and Friker, Lea L and Keupp, Jochen and Katemann, Christoph and Layer, Julian P and Schaub, Christina and Gkika, Eleni and Vatter, Hartmut and Pietsch, Torsten and Radbruch, Alexander and Herrlinger, Ulrich and Paech, Daniel},
title = {Amide proton transfer-weighted (APTw) CEST MRI in clinical routine for single time point diagnosis of pseudoprogression in IDH-wildtype glioblastoma},
journal = {Neuro-Oncology},
year = {2026},
volume = {28},
number = {3},
pages = {790--801},
doi = {10.1093/neuonc/noaf261}
}
EUVIMED